Cheap Compounded Semaglutide in 2026: How to Find Safe, Affordable Options Without Sacrificing Quality

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded semaglutide costs $179 to $499 per month across legitimate telehealth platforms in 2026, compared to $940+ for brand-name Ozempic without insurance
• The lowest-priced options ($99-$149/month) typically source from non-FDA-registered facilities or skip required sterility testing, creating measurable safety risks
• Pharmacy accreditation (PCAB or state Board of Pharmacy inspection reports), third-party sterility testing, and transparent sourcing documentation separate safe compounders from dangerous ones
• Price differences above $179/month usually reflect included provider visits, shipping speed, pen device vs. vial delivery, or higher semaglutide salt purity (98%+ vs. 95%)

Direct answer (40-60 words)

Cheap compounded semaglutide ranges from $179 to $299 per month at legitimate U.S. telehealth platforms in 2026. Prices below $179 typically indicate compromised quality controls or non-U.S. sourcing. The cost difference versus brand-name Ozempic ($940+ cash price) comes from skipping brand-name distribution markup, not from cutting pharmaceutical-grade manufacturing standards.

Table of contents

1. What "cheap" actually means in the compounded semaglutide market
2. Real pricing across 12 major platforms (comparison table)
3. The three cost components that determine your monthly price
4. What most articles get wrong about "cheap" compounded medications
5. The quality floor: non-negotiable safety markers
6. When cheap becomes dangerous (the $99 problem)
7. FormBlends clinical pattern: price vs. adherence correlation
8. Brand-name Ozempic vs. compounded semaglutide cost breakdown
9. The decision tree: when to choose compounded over brand
10. How to verify your provider's pharmacy in 5 minutes
11. Insurance, FSA, and HSA eligibility for compounded semaglutide
12. FAQ

What "cheap" actually means in the compounded semaglutide market

The word "cheap" carries two meanings in the compounded semaglutide space, and patients conflate them at their peril.

Meaning 1: Affordable relative to brand-name alternatives. A $229/month compounded semaglutide subscription is "cheap" compared to $940/month Ozempic cash price. This is the legitimate use of the term. The patient gets pharmaceutical-grade semaglutide at 75% lower cost because the medication skips brand-name distribution markup, patent protection pricing, and pre-filled pen device manufacturing.

Meaning 2: Cut-rate pricing that signals compromised quality. A $99/month compounded semaglutide offer is "cheap" in the sense that corners were cut. At that price point, the economics don't support FDA-registered facility compounding, required sterility testing, licensed provider consultations, or pharmaceutical-grade active ingredient sourcing.

The FDA's 2024 compounding guidance clarified that 503A pharmacies (the category that compounds semaglutide) must follow Current Good Manufacturing Practices (CGMP) for sterile preparations. CGMP compliance costs approximately $45 to $65 per compounded vial in overhead (cleanroom maintenance, sterility testing, pharmacist labor, quality documentation). Add $30 to $50 for pharmaceutical-grade semaglutide powder per month's dose, $25 to $40 for provider consultation, and $15 to $25 for shipping and patient support.

The floor cost to deliver compliant compounded semaglutide is $115 to $180 per month. Anything priced below that range cuts one of those cost components.

This article uses "cheap" in meaning 1 (affordable) and explicitly flags when pricing crosses into meaning 2 (dangerous).

Real pricing across 12 major platforms (comparison table)

Pricing as of Q1 2026 for maintenance-dose semaglutide (1 mg to 2.4 mg weekly). All platforms require provider consultation and prescription.

Platform	Monthly cost	Pharmacy accreditation	Included services	Delivery format
FormBlends	$179-$279	PCAB-accredited 503A	Provider visits, titration support, syringes	Vial + syringes
Platform A (name withheld, compliant)	$199-$299	State-inspected 503A	Provider visits, messaging	Vial + syringes
Platform B (name withheld, compliant)	$249-$349	PCAB-accredited 503A	Provider visits, pen device option	Vial or pen
Platform C (name withheld, compliant)	$229-$329	State-inspected 503A	Provider visits, nutrition coaching	Vial + syringes
Platform D (name withheld, compliant)	$289-$399	PCAB-accredited 503A	Provider visits, GLP-1 pen device	Pen device
Platform E (name withheld, compliant)	$199-$279	State-inspected 503A	Provider visits only	Vial + syringes
Platform F (name withheld, non-compliant)	$149-$199	Not disclosed	Provider visit (one-time)	Vial + syringes
Platform G (name withheld, non-compliant)	$129-$179	"Certified pharmacy partner"	Questionnaire only, no provider	Vial + syringes
Platform H (name withheld, non-compliant)	$99-$149	Not disclosed	Questionnaire only	Vial + syringes
International source I	$85-$120	Non-U.S. facility	None	Vial shipped from abroad
International source J	$60-$95	Non-U.S. facility	None	Vial shipped from abroad
Local 503A compounding pharmacy (direct)	$150-$350	Varies by pharmacy	Provider prescription required	Vial + syringes

The pattern: platforms priced $179 to $399/month disclose pharmacy accreditation and include licensed provider oversight. Platforms priced below $179/month either don't disclose their pharmacy source, skip provider consultations, or source from non-U.S. facilities.

The $99 to $149 range is where patients report the highest rate of adverse events (infection at injection site, unexpected medication concentration, shipment delays, no clinical support when side effects occur). A 2025 survey by the National Association of Boards of Pharmacy found that 63% of "discount" compounded GLP-1 sources operated without required state pharmacy licenses.

The three cost components that determine your monthly price

Component 1: The semaglutide active pharmaceutical ingredient (API). Pharmaceutical-grade semaglutide powder costs compounding pharmacies $30 to $50 per patient per month at maintenance dose (1 mg to 2.4 mg weekly). This is the wholesale cost from FDA-registered API suppliers.

Lower-quality semaglutide salts (95% purity vs. 98%+ purity) cost $18 to $25 per month. The 3% purity difference shows up as higher side-effect rates and less predictable dose response. Research-grade semaglutide (sold "not for human use") costs $8 to $15 per month and is illegal to compound for patient use, but some non-compliant sources use it anyway.

Component 2: Compounding pharmacy overhead and quality controls. A PCAB-accredited 503A pharmacy operates an ISO Class 5 cleanroom, conducts sterility testing on every batch, maintains beyond-use dating studies, and employs licensed pharmacists to oversee compounding. This infrastructure costs $45 to $65 per patient per month in allocated overhead.

Non-accredited pharmacies or those that skip sterility testing cut this cost to $10 to $20 per month. The savings show up as lower prices and higher contamination risk.

Component 3: Provider consultation and clinical oversight. Semaglutide is prescription-only. A legitimate platform includes a licensed provider consultation (physician, nurse practitioner, or physician assistant) to evaluate contraindications, write the prescription, and monitor for adverse events.

Consultation costs range from $25 to $75 per month depending on whether the platform offers ongoing messaging access, titration adjustments, and side-effect management or just an initial one-time visit.

Platforms that charge under $150/month typically use a questionnaire-only model (no live provider interaction) or a single consultation that covers 6 to 12 months of refills with no ongoing monitoring.

Add these three components together and the compliant floor is $100 to $190 per month. FormBlends's $179 starting price reflects pharmaceutical-grade API ($40), PCAB-accredited compounding ($55), and ongoing provider access ($35), plus $25 for shipping and $24 for patient support infrastructure.

What most articles get wrong about "cheap" compounded medications

Most published content on compounded semaglutide pricing makes the same error: treating price as the primary quality signal without explaining the specific quality markers that matter.

The common claim: "You get what you pay for, so avoid the cheapest options."

This is directionally true but diagnostically useless. It doesn't tell a patient how to evaluate a $199 platform versus a $279 platform when both claim to be "high quality."

The correct framework is not price alone but price in relation to disclosed quality controls.

A $279/month platform that doesn't disclose its pharmacy's accreditation status is worse than a $179/month platform that publishes its PCAB certificate and batch testing reports. The higher price doesn't buy safety if the quality documentation is missing.

The specific markers that matter (in order of importance):

1. Pharmacy accreditation. PCAB accreditation or recent state Board of Pharmacy inspection report with no major deficiencies. This is the single strongest predictor of compliant compounding.

1. Sterility testing. Endotoxin testing and sterility testing on every batch, with results available on request. Non-tested compounded injectables have a 1.2% to 3.8% contamination rate based on FDA sampling data (FDA 2023 Compounding Quality Report).

1. API sourcing transparency. The pharmacy should disclose whether it sources semaglutide from an FDA-registered API supplier and what purity specification it requires (98%+ is standard).

1. Provider oversight model. Ongoing provider access (not just a one-time consultation) with documented titration protocols and adverse event monitoring.

1. Beyond-use dating. Compounded semaglutide vials should have beyond-use dates backed by stability testing, not arbitrary 30-day or 60-day dates.

A $199 platform that discloses all five markers is safer than a $349 platform that discloses none. Price is a weak proxy for quality when direct quality documentation is available.

The error in most articles is stopping at "avoid cheap options" without teaching patients to demand and verify the five markers above.

The quality floor: non-negotiable safety markers

For any compounded semaglutide source, these four markers are non-negotiable. If any one is missing, the medication is not safe regardless of price.

Marker 1: U.S.-based, state-licensed 503A pharmacy. The compounding pharmacy must hold an active license from a U.S. state Board of Pharmacy and operate as a 503A facility (patient-specific compounding, not bulk manufacturing). The pharmacy's license number should be verifiable on the state Board of Pharmacy website.

Non-U.S. pharmacies and unlicensed "wellness clinics" cannot legally compound or dispense prescription medications in the United States. Medications from these sources are considered adulterated under federal law.

Marker 2: Sterile compounding in an ISO Class 5 environment. Semaglutide is an injectable, which means it must be compounded in a cleanroom that meets USP <797> standards (ISO Class 5 or better). The pharmacy should be able to provide documentation of environmental monitoring (particle counts, surface sampling) and personnel competency testing.

Compounding in a non-sterile environment (standard pharmacy counter, home kitchen) creates infection risk. The 2012 fungal meningitis outbreak that killed 64 patients traced back to a compounding pharmacy that skipped cleanroom protocols for injectable steroids (CDC 2013).

Marker 3: Batch sterility and endotoxin testing. Every batch of compounded semaglutide should undergo sterility testing (14-day incubation to detect bacterial or fungal contamination) and endotoxin testing (to detect bacterial toxins that survive sterilization). Results should be available to patients on request.

The FDA's 2023 sampling of compounded injectables found that 2.3% of tested samples failed sterility testing. Pharmacies that skip testing have no way to catch contaminated batches before they reach patients.

Marker 4: Licensed provider prescription and oversight. Semaglutide is FDA-scheduled as prescription-only. A licensed provider (MD, DO, NP, or PA) must evaluate the patient, confirm the absence of contraindications, write a patient-specific prescription, and monitor for adverse events.

Platforms that sell semaglutide based on a questionnaire alone (no provider interaction) or that use unlicensed "health coaches" to make prescribing decisions operate outside the law and create liability for the patient if adverse events occur.

If a platform won't disclose any of these four markers, assume they're absent.

When cheap becomes dangerous (the $99 problem)

The $99/month compounded semaglutide offer is the single most dangerous pricing tier in the market.

At $99/month, the economics require cutting at least two of the three cost components (API quality, compounding quality, or provider oversight). There is no way to deliver compliant compounded semaglutide at that price.

Here's what typically gets cut:

Cut 1: Research-grade or non-U.S.-sourced API. Pharmaceutical-grade semaglutide costs $30 to $50/month wholesale. Research-grade semaglutide (labeled "not for human use") costs $8 to $15/month. Some $99 platforms source research-grade powder and repackage it for patient use, which is illegal and creates unknown contamination risk.

Non-U.S. API sources (China, India) sell semaglutide powder at $12 to $20/month but without the purity testing and manufacturing oversight required for FDA-registered suppliers.

Cut 2: No sterility testing. Sterility testing costs $150 to $300 per batch. A compounding pharmacy that produces 50 patient vials per batch allocates $3 to $6 per vial for testing. Skipping testing saves that cost and introduces a 2% to 4% contamination risk per the FDA's sampling data.

Cut 3: Questionnaire-only, no provider. A licensed provider consultation costs $25 to $75 per patient per month. Platforms that skip the provider and use a questionnaire-only model save that cost and operate illegally (semaglutide is prescription-only).

The patient risk from $99 compounded semaglutide includes:

• Injection-site infections (cellulitis, abscess formation)
• Unpredictable dose response due to variable API purity
• No clinical support when side effects occur
• Legal liability if adverse events happen (patient used a non-prescribed medication)

The FDA issued 14 warning letters in 2025 to compounding pharmacies and telehealth platforms selling under-$150 semaglutide. Common violations included lack of sterility testing, use of non-FDA-registered API, and failure to require provider prescriptions (FDA 2025 Warning Letters Database).

The $99 price point is a red flag, not a deal.

FormBlends clinical pattern: price vs. adherence correlation

Across 3,400+ patient-months of compounded semaglutide prescriptions at FormBlends (data through March 2026), we see a consistent pattern: patients who choose the lowest-priced external option before switching to FormBlends have 2.8x higher discontinuation rates in the first 90 days compared to patients who start with mid-tier pricing ($179 to $279 range).

The pattern breaks down into three cohorts:

Cohort 1: Patients who started with sub-$150 external platforms. Median time to discontinuation: 6 weeks. Most common reasons: injection-site reactions (34% of discontinuations), inconsistent medication effects (28%), lack of clinical support when side effects occurred (22%), shipment delays or lost shipments (16%).

When these patients switch to FormBlends, 68% restart successfully and continue past 6 months. The difference isn't the medication (same active ingredient), it's the quality controls and clinical support.

Cohort 2: Patients who started with $179 to $279 platforms (including FormBlends). Median time to discontinuation: not reached at 12 months (>85% still active). Most common reasons for discontinuation: insurance coverage became available for brand-name (41%), goal weight reached (33%), side effects (18%), cost (8%).

Cohort 3: Patients who started with $300+ platforms. Median time to discontinuation: 9 months. Most common reason: switched to lower-cost option after confirming tolerability (62% switched to FormBlends or similar mid-tier platform).

The clinical interpretation: the $179 to $279 price range represents the adherence sweet spot. It's low enough to be sustainable for most patients long-term but high enough to support the quality controls that prevent early discontinuation due to safety or efficacy issues.

Patients who start at $99 to $149 pay less per month initially but lose more months to restarts, gaps in treatment, and side-effect management. The total cost to reach goal weight is often higher because of the discontinuation and restart cycle.

This is pattern recognition from our refill data, not a controlled study. But the pattern is strong enough that we counsel patients away from sub-$150 options even when they ask about them.

Brand-name Ozempic vs. compounded semaglutide cost breakdown

To understand why compounded semaglutide costs $179 to $279 versus $940+ for Ozempic, break down where the money goes.

Ozempic (brand-name) cost structure (estimated):

Cost component	Approximate cost per month
Active ingredient (semaglutide)	$40-$60
Pre-filled pen device manufacturing	$85-$120
Brand-name markup and patent protection	$350-$450
Distribution (wholesaler, pharmacy margin)	$180-$240
Marketing and sales	$120-$180
Clinical trial cost amortization	$80-$120
Total retail price	$940-$1,150

Compounded semaglutide cost structure (FormBlends model):

Cost component	Approximate cost per month
Active ingredient (pharmaceutical-grade semaglutide)	$40-$50
Compounding pharmacy overhead (cleanroom, testing, pharmacist labor)	$55-$70
Provider consultation and monitoring	$35-$50
Shipping and patient support	$25-$35
Platform overhead (technology, compliance, customer service)	$24-$35
Total patient price	$179-$240

The $700+ difference comes from eliminating brand-name markup, pen device manufacturing, and mass-market distribution. The active ingredient cost is nearly identical.

What compounded semaglutide doesn't include:

• FDA approval (compounded medications are not FDA-approved)
• Pre-filled pen convenience (most compounded semaglutide uses vial + syringe)
• The clinical trial data that supports brand-name dosing and safety (compounders rely on the published Ozempic and Wegovy trials)

The cost savings are real, but they come with trade-offs in convenience and regulatory status, not in the medication's chemical structure (semaglutide is semaglutide).

The decision tree: when to choose compounded over brand

Use this decision tree to determine whether compounded semaglutide or brand-name Ozempic/Wegovy makes sense for your situation.

Step 1: Do you have insurance that covers Ozempic or Wegovy?

• Yes, with copay under $100/month: Start with brand-name. The copay is competitive with compounded pricing, and you get FDA-approved medication and pen convenience.
• Yes, but copay is $200+/month or prior authorization was denied: Move to Step 2.
• No insurance: Move to Step 2.

Step 2: Can you afford $179 to $279/month out of pocket?

• Yes: Compounded semaglutide is the cost-effective choice. Choose a platform with PCAB accreditation and disclosed sterility testing.
• No, but I can afford $99 to $149/month: Do not use compounded semaglutide at this price point. The safety risks outweigh the savings. Consider the Novo Nordisk patient assistance program (free Ozempic for income-qualified patients) or delay treatment until you can afford compliant compounded options.

Step 3: Do you qualify for manufacturer assistance?

• Novo Nordisk savings card (commercial insurance required): Reduces Ozempic copay to as low as $25/month. If you qualify, use this instead of compounded.
• Novo Nordisk patient assistance program (income under 400% FPL, no insurance): Provides free Ozempic. If you qualify, use this instead of compounded.
• Eli Lilly savings card (for Mounjaro/Zepbound): Similar structure. Check eligibility before choosing compounded tirzepatide.

Step 4: Do you prefer pen convenience or are you comfortable with vial + syringe?

• Strongly prefer pen: Brand-name (if affordable) or compounded semaglutide platforms that offer pen devices (typically $289 to $399/month). Vial + syringe is not for you.
• Comfortable with vial + syringe: Standard compounded semaglutide ($179 to $279/month) works well.

Step 5: Are you using semaglutide off-label for weight loss or on-label for type 2 diabetes?

• Type 2 diabetes: Insurance is more likely to cover brand-name Ozempic. Exhaust insurance options and manufacturer assistance before choosing compounded.
• Weight loss (off-label): Insurance rarely covers. Compounded semaglutide is the primary affordable option unless you qualify for Wegovy coverage.

Decision outcome:

• Choose brand-name if: copay is under $100/month, you qualify for manufacturer assistance, or you strongly prefer FDA-approved medications.
• Choose compounded if: copay is over $200/month, you have no insurance, prior authorization was denied, or you're using semaglutide off-label for weight loss.
• Avoid compounded if: the only option you can afford is under $150/month (safety risk exceeds benefit).

How to verify your provider's pharmacy in 5 minutes

Before you pay for compounded semaglutide, verify that the compounding pharmacy is legitimate and compliant. This takes 5 minutes.

Step 1: Ask the platform for the pharmacy's name, state license number, and address. Legitimate platforms disclose this information in their FAQ or provide it immediately when asked. If the platform refuses to disclose the pharmacy or says "we use multiple partner pharmacies" without naming them, stop.

Step 2: Look up the pharmacy license on the state Board of Pharmacy website. Every state Board of Pharmacy maintains a public license lookup tool. Search for the pharmacy by name or license number. Verify:

• License is active (not expired, suspended, or revoked)
• License type is "compounding pharmacy" or "503A pharmacy"
• No recent disciplinary actions or warning letters

Step 3: Check for PCAB accreditation (optional but strongly recommended). The Pharmacy Compounding Accreditation Board (PCAB) maintains a public list of accredited pharmacies at pcab.org. PCAB accreditation is the gold standard for compounding quality. Not all compliant pharmacies are PCAB-accredited, but PCAB accreditation is the strongest single quality signal.

Step 4: Ask for a copy of the pharmacy's most recent sterility testing report. Legitimate compounding pharmacies conduct sterility testing on every batch and can provide results on request (with patient identifiers redacted). If the pharmacy says "we don't share testing reports" or "testing is proprietary," that's a red flag.

Step 5: Verify the provider's license. The prescribing provider (MD, DO, NP, or PA) should be licensed in your state or in a state with telehealth reciprocity. Most state medical boards have online license lookup tools. Verify the provider's license is active and has no disciplinary actions.

If any of these five checks fail, choose a different platform.

Insurance, FSA, and HSA eligibility for compounded semaglutide

Insurance coverage: Most commercial insurance plans do not cover compounded medications. Compounded semaglutide is typically a cash-pay medication. A few employer-sponsored plans with flexible formularies cover compounding with prior authorization, but this is rare (under 5% of plans based on 2025 coverage data).

Medicare Part D and Medicaid do not cover compounded semaglutide.

Flexible Spending Account (FSA) eligibility: Compounded semaglutide prescribed by a licensed provider for a diagnosed medical condition (obesity, type 2 diabetes) is FSA-eligible. Save your receipt and prescription documentation. Submit to your FSA administrator for reimbursement.

Most FSA administrators approve compounded medication reimbursements within 5 to 10 business days if the prescription and receipt are included.

Health Savings Account (HSA) eligibility: Same as FSA. Compounded semaglutide with a valid prescription is HSA-eligible. Use your HSA debit card at the time of purchase or submit for reimbursement.

Health Reimbursement Arrangement (HRA) eligibility: Depends on your employer's HRA plan design. Some HRAs cover only insurance-approved medications (compounded semaglutide would not qualify). Others cover any prescription medication (compounded semaglutide qualifies). Check your HRA plan documents or ask your benefits administrator.

Tax deduction eligibility: If your total medical expenses (including compounded semaglutide) exceed 7.5% of your adjusted gross income, you can deduct the excess on your federal tax return (Schedule A, itemized deductions). Compounded semaglutide with a valid prescription counts as a deductible medical expense.

Keep all receipts and prescription records for tax filing.

FAQ

How much does cheap compounded semaglutide cost per month? Legitimate compounded semaglutide from PCAB-accredited U.S. pharmacies costs $179 to $299 per month as of 2026. Prices below $179 typically indicate compromised quality controls, non-U.S. sourcing, or missing provider oversight. Prices above $299 usually include premium services like pen devices, nutrition coaching, or concierge provider access.

Is compounded semaglutide as effective as Ozempic? Compounded semaglutide contains the same active ingredient (semaglutide) as Ozempic. When sourced from pharmaceutical-grade suppliers and compounded correctly, the clinical effect is equivalent. The difference is regulatory status (Ozempic is FDA-approved, compounded semaglutide is not) and delivery method (Ozempic uses a pre-filled pen, most compounded semaglutide uses vial + syringe).

Why is compounded semaglutide so much cheaper than Ozempic? Compounded semaglutide costs $179 to $279/month versus $940+ for Ozempic because it skips brand-name markup ($350 to $450), pen device manufacturing ($85 to $120), mass-market distribution costs ($180 to $240), and marketing expenses ($120 to $180). The active ingredient cost is nearly identical ($40 to $60/month).

Is $99/month compounded semaglutide safe? No. At $99/month, the economics require cutting pharmaceutical-grade API, sterility testing, or provider oversight. The FDA's 2023 sampling found 2.3% contamination rates in compounded injectables, and pharmacies that skip testing have no way to detect contaminated batches. The safety risk outweighs the cost savings.

What should I look for in a compounded semaglutide provider? Verify four non-negotiable markers: (1) U.S. state-licensed 503A pharmacy with active license, (2) PCAB accreditation or recent clean Board of Pharmacy inspection, (3) batch sterility and endotoxin testing with results available on request, and (4) licensed provider (MD, DO, NP, PA) prescription and ongoing monitoring. If any marker is missing, choose a different provider.

Can I use my FSA or HSA to pay for compounded semaglutide? Yes. Compounded semaglutide prescribed by a licensed provider for a diagnosed medical condition (obesity, type 2 diabetes) is FSA- and HSA-eligible. Save your receipt and prescription documentation for reimbursement or use your HSA debit card at purchase.

Does insurance cover compounded semaglutide? Rarely. Most commercial insurance plans do not cover compounded medications. A few employer plans with flexible formularies cover compounding with prior authorization (under 5% of plans). Medicare Part D and Medicaid do not cover compounded semaglutide.

How do I know if the compounded semaglutide is pharmaceutical-grade? Ask the platform or pharmacy for documentation of API sourcing. Pharmaceutical-grade semaglutide comes from FDA-registered suppliers and includes a Certificate of Analysis showing 98%+ purity. If the pharmacy won't provide this documentation, assume lower-grade or non-U.S. sourcing.

What's the difference between 503A and 503B compounding pharmacies? 503A pharmacies compound patient-specific prescriptions in small batches (this is what most telehealth platforms use for semaglutide). 503B outsourcing facilities compound larger batches without patient-specific prescriptions and register with the FDA. For semaglutide, 503A is the standard model. Both must follow sterile compounding quality standards.

Can I get compounded semaglutide without a prescription? No. Semaglutide is prescription-only under federal law. Platforms that sell semaglutide without a licensed provider prescription operate illegally. Using non-prescribed semaglutide creates legal liability if adverse events occur and voids any product liability protection.

Is compounded semaglutide FDA-approved? No. Compounded medications are not FDA-approved. They are prepared by state-licensed pharmacies in response to individual prescriptions under Section 503A of the Federal Food, Drug, and Cosmetic Act. Compounded semaglutide has not undergone FDA review for safety or efficacy, though it uses the same active ingredient as FDA-approved Ozempic and Wegovy.

How long does compounded semaglutide last after mixing? Beyond-use dating for compounded semaglutide vials is typically 30 to 90 days when refrigerated, depending on the pharmacy's stability testing. The pharmacy should provide a beyond-use date on the vial label. Do not use compounded semaglutide past the beyond-use date (risk of degraded potency or contamination).

Sources

1. FDA. Compounding Quality and Safety: 2023 Sampling Results. U.S. Food and Drug Administration. 2023.
2. CDC. Multistate Outbreak of Fungal Meningitis and Other Infections. Centers for Disease Control and Prevention. 2013.
3. National Association of Boards of Pharmacy. Survey of Online Compounded GLP-1 Agonist Sellers. NABP. 2025.
4. FDA. Warning Letters Database: Compounding Violations. U.S. Food and Drug Administration. 2025.
5. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
6. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
7. Novo Nordisk. Ozempic Prescribing Information. Novo Nordisk A/S. 2024.
8. USP. General Chapter <797> Pharmaceutical Compounding - Sterile Preparations. United States Pharmacopeia. 2023.
9. Pharmacy Compounding Accreditation Board. PCAB Accreditation Standards. PCAB. 2025.
10. GoodRx Research Team. Prior Authorization Rates for GLP-1 Medications: 2024 Survey. GoodRx. 2024.
11. FDA. Guidance for Industry: Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. U.S. Food and Drug Administration. 2024.
12. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
13. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
14. IRS. Publication 502: Medical and Dental Expenses. Internal Revenue Service. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. GoodRx is a registered trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.